▲ Peaking
World
🔮 holds ✗
The Pharma Letter
Coverage by The Pharma Letter as tracked by Newsylist.
11trends covered
0broke first
11articles tracked
◼ Archived
Health
🔮 holds ✗
Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B
◼ Archived
Business
🔮 holds ✗
Servier’s $1.5B bet on Edgewise drug fails five months in
◼ Archived
Business
🔮 fades ✓
AstraZeneca blames trial design for Phase 3 failure of bone disease drug
◼ Archived
Business
🔮 holds ✗
High cost of GLP-1s drives some to seek cheaper, unregulated versions
◼ Archived
Business
🔮 holds ✗
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
◼ Archived
Business
🔮 holds ✗
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
◼ Archived
Business
🔮 holds ✗
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
◼ Archived
Business
🔮 holds ✗
Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
◼ Archived
Health
🔮 holds ✗
As weight loss drugs like Ozempic spread, Louisiana doctors, researchers help answer big questions
Medical researchers and clinicians are investigating whether GLP-1 weight loss drugs like Ozempic offer benefits beyond weight reduction, including longevity.
◼ Archived
Business
🔮 holds ✗
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
Eli Lilly shares surge following a CHMP recommendation for Jaypirca's EU approval to treat chronic lymphocytic leukemia.